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Summary
Metastatic disease is the primary cause of death in breast cancer, the most common malignancy in Western women. Loss of
E-cadherin is associated with tumor metastasis, as well as with invasive lobular carcinoma (ILC), which accounts for 10%–
15% of all breast cancers. To study the role of E-cadherin in breast oncogenesis, we have introduced conditional E-cadherin
mutations into a mouse tumor model based on epithelium-specific knockout of p53. Combined loss of E-cadherin and p53
resulted in accelerated development of invasive and metastatic mammary carcinomas, which show strong resemblance to
human ILC. Moreover, loss of E-cadherin induced anoikis resistance and facilitated angiogenesis, thus promoting meta-
static disease. Our results suggest that loss of E-cadherin contributes to both mammary tumor initiation and metastasis.Introduction
Breast cancer is the most common malignancy among females
in the Western world, affecting 12% of the female population
and resulting in approximately half a million deaths annually
(Althuis et al., 2005). Invasive lobular carcinoma (ILC), which rep-
resents 10%–15% of all breast cancers, has a greater tendency
for multifocality and bilaterality than other primary breast tumors
(Arpino et al., 2004). In its classical form, ILC consists of nonco-
hesive cells that invade the parenchyma diffusely or arranged in
trabecules without mass formation, often resulting in a false-
negative diagnosis using physical examination or mammogra-
phy (Simpson et al., 2003).
Breast cancer progression depends on the capacity to invade
and to metastasize to distant sites. Loss of tumor cell adhesion
is an important factor in this process. E-cadherin is a key com-
ponent of adherens junctions, structures that play crucial roles
in the maintenance of epithelial integrity (Perez-Moreno et al.,
2003). E-cadherin is a calcium-dependent cell adhesion mole-
cule that mediates homophilic interactions and controls theCANCER CELL 10, 437–449, NOVEMBER 2006 ª2006 ELSEVIER INC. Dformation of catenin-containing complexes that link E-cadherin
to the actin and microtubule cytoskeleton (Hulsken et al., 1994;
Takeichi, 1995; Perez-Moreno et al., 2003). In cancer, loss of
E-cadherin function through genetic or epigenetic mechanisms
has been implicated in progression and metastasis of numer-
ous malignancies (Vleminckx et al., 1991; Frixen et al., 1991;
Oda et al., 1994; Cleton-Jansen et al., 1994; Berx et al., 1995; Graff
et al., 1995; Yoshiura et al., 1995; Savagner et al., 1997; Perl
et al., 1998; Batlle et al., 2000; Cano et al., 2000; Comijn et al.,
2001; Fujita et al., 2003; Yang et al., 2004; Moody et al., 2005).
In breast cancer, the vast majority of ILCs have lost expression
of E-cadherin, whereas most other subtypes have retained
expression (Berx et al., 1995; Lehr et al., 2000; Korkola et al.,
2003; Zhao et al., 2004). While metastasis to lung, liver, and
bone marrow is common in most types of human breast cancer,
including ILC, gastrointestinal and peritoneal metastases are
more frequent in ILC (Arpino et al., 2004).
Although the expression and mutational status of E-cadherin
may serve as a prognostic indicator in breast pathology, its
contribution to tumor initiation, progression, and metastasis isS I G N I F I C A N C E
Human invasive lobular carcinoma (ILC) is the second most common type of primary breast cancer. ILC is often difficult to diagnose
and shows overall poor responses to conventional chemotherapy. This study shows that tissue-specific loss of E-cadherin and p53 in
mice induces metastatic mammary carcinomas that resemble human ILC. The mouse model presented here provides a valuable
tool to gain insights into the role of E-cadherin loss of function in mammary tumor initiation, progression, and metastasis and may ulti-
mately contribute to the development of therapies for the treatment of lobular breast cancer.OI 10.1016/j.ccr.2006.09.013 437
A R T I C L Elargely undefined. We therefore sought to study the conse-
quences of somatic loss of E-cadherin in a mouse mammary tu-
mor model based on epithelium-specific inactivation of p53. The
data presented here show that combined loss of E-cadherin and
p53 in mammary epithelial cells induces metastatic carcinomas
that resemble human ILC.
Results
Conditional inactivation of E-cadherin alone does
not induce tumor formation
To study the effects of E-cadherin loss on skin and mammary tu-
morigenesis, we employed conditional E-cadherin (Cdh1) gene
inactivation using the Cre/loxP site-specific recombination sys-
tem (Figures S1A–S1C in the Supplemental Data available with
this article online) and crossed the resulting Cdh1F conditional
animals with K14cre transgenic mice (Figure S1D), which ex-
press the Cre recombinase in several epithelial tissues, includ-
ing skin and mammary epithelium (Jonkers et al., 2001). In line
with the low and stochastic K14cre recombinase activity in
mammary epithelium (Jonkers et al., 2001), no abnormal ductal
and alveolar development was observed in virgin, pregnant, or
parous K14cre;Cdh1F/F mice, and dams were able to nurse their
litters (data not shown). K14cre-mediated loss of E-cadherin
alone does not predispose to cancer, as none of the
K14cre;Cdh1F/F animals developed skin or mammary tumors.
These findings are consistent with previous work showing that
conditional inactivation of E-cadherin in either skin or mammary
epithelium does not induce tumor formation (Boussadia et al.,
2002; Young et al., 2003; Tinkle et al., 2004; Tunggal et al., 2005).
E-cadherin loss collaborates with p53 loss in skin
and mammary tumorigenesis
To study the effects of E-cadherin loss on mammary tumor
initiation, progression, and metastasis, we made use of the
K14cre;Trp53F/F mouse tumor model, which gives rise to mam-
mary carcinomas and carcinosarcomas with a median latency of
330 days (X.L., H. Holstege, H.v.d.G., M. Treur, J.Z., A. Velds,
R.M. Kerkhoven, M. van Vliet, L.F.A. Wessels, J.L.P., A.B., and
J.J., unpublished data). Furthermore, squamous cell carcino-
mas of the skin developed in approximately 25% of the
K14cre;Trp53F/F females. As most carcinomas in K14cre;
Trp53F/F animals are nonmetastatic, this model is suitable for in-
vestigating phenotypic consequences of additional mutations in
genes implicated in tumor progression and metastasis. We
therefore introduced the Cdh1F allele into the K14cre;Trp53F/F
model to produce K14cre;Cdh1F/F;Trp53F/F, K14cre;Cdh1F/+;
Trp53F/F, and K14cre;Cdh1F/F;Trp53F/+ females, which were
monitored for spontaneous tumor development and progres-
sion. Homozygous mutation of E-cadherin resulted in acceler-
ated development of skin and mammary tumors in K14cre;
Cdh1F/F;Trp53F/F female mice, compared to the K14cre;
Trp53F/F females (p < 0.0001; Figure 1A, left panels, and Fig-
ure S2), demonstrating that E-cadherin loss of function collabo-
rates with p53 inactivation in epithelial tumorigenesis. K14cre;
Cdh1F/F;Trp53F/F mice developed multiple skin and mammary
tumors with a median latency of 214 days. In contrast,
K14cre;Trp53F/F females developed mostly single mammary
tumors and small numbers of skin carcinomas with a median
latency of 330 days. We observed significantly longer tumor la-
tency periods for K14cre;Cdh1F/+;Trp53F/F and K14cre;Cdh1F/F;438Trp53F/+ females (330 and 495 days, respectively; p < 0.0001;
Figure 1A, upper right and lower left panels, and Figure S2),
showing that E-cadherin and p53 loss of function effectively
synergize in skin and mammary tumorigenesis.
We next determined the genetic status of Cdh1 and Trp53 in
the panels of mammary tumors derived from the different com-
pound mutant mouse strains. Southern blot analysis showed
stochastic loss of the conditional Cdh1 allele in tumors derived
from K14cre;Cdh1F/+;Trp53F/F animals, whereas the wild-type
Cdh1 allele was retained (Figure 1B). Because the tumor-free
survival curves for the K14cre;Cdh1F/+;Trp53F/F and K14cre;
Trp53F/F females were identical (Figure 1A, lower right panel),
we conclude that E-cadherin is not haploinsufficient for tumor
suppression. In contrast to the stochastic loss of the conditional
Cdh1 allele in K14cre;Cdh1F/+;Trp53F/F mammary tumors, we
detected uniform loss of both conditional Cdh1 alleles in the
majority of mammary tumors from K14cre;Cdh1F/F;Trp53F/+
and K14cre;Cdh1F/F;Trp53F/F females (Figure 1B). We also de-
tected loss of the conditional and wild-type Trp53 alleles in all
mammary tumors from K14cre;Cdh1F/+;Trp53F/F, K14cre;
Cdh1F/F;Trp53F/+, and K14cre;Cdh1F/F;Trp53F/F females (Fig-
ure 1B), indicating that, in these mice, loss of functional p53 is
a prerequisite for mammary tumor formation.
Loss of E-cadherin and p53 induces invasive skin
carcinoma
Skin tumors from K14cre;Trp53F/F or K14cre;Cdh1F/+;Trp53F/F
mice could be classified as either pilomatricomas or squamous
cell carcinomas with expansive growth patterns without evident
metastasis (Figure S3, left panels). In contrast, homozygous
mutation of E-cadherin in K14cre;Cdh1F/F;Trp53F/F and
K14cre;Cdh1F/F;Trp53F/+ animals had a dramatic impact on
skin tumor phenotype. Skin tumors from these animals often
showed a phenotypic change from expansive to invasive growth
(Figure S3, right panels). Tumors invaded subcutaneous fat and
carnosus muscle in irregular strands and nest with polymorphic
cells with dyskeratosis (Figure S3, right panels). Tumor cells
expressed cytokeratin 14 (CK14) (Figures S3C and S3D) but
lacked expression of CK1 and CK6 (data not shown), suggesting
a basal origin. Occasionally, draining lymph nodes contained
malignant epithelial cells, but distant metastases were absent.
Loss of E-cadherin induces a shift from expansive
carcinoma to invasive lobular carcinoma
Mostmammary tumors fromK14cre;Trp53F/ForK14cre;Cdh1F/+;
Trp53F/F females were diagnosed as intermediate-grade adeno-
carcinomas or high-grade solid carcinomas, characterized by an
expansive growth pattern and consisting of large epithelial cells
forming solid nests or irregular glands (X.L., H. Holstege,
H.v.d.G., M. Treur, J.Z., A. Velds, R.M. Kerkhoven, M. van Vliet,
L.F.A. Wessels, J.L.P., A.B., and J.J., unpublished data, and
Figure 2, left panels). Adenocarcinomas and solid carcinomas
uniformly expressed CK8 and showed occasional sporadic ex-
pression of CK14 but lacked expression of vimentin (Figure 2,
left panels; Table S1) and smooth muscle actin (SMA; data not
shown). The third most common tumor type shows a carcinosar-
coma phenotype, characterized by a metaplastic and biphasic
histology comprised of epithelial and mesenchymal elements.
These tumors show a heterogeneous expression pattern for CK8
and 14, often express vimentin, and mostly lack expression of
E-cadherin (Table S1). Adenocarcinomas and solid carcinomasCANCER CELL NOVEMBER 2006
A R T I C L EFigure 1. Synergistic tumor suppressor activity of E-cadherin and p53
A: Tumor incidence and spectrum of tumors in K14cre females carrying conditional alleles for Cdh1 and Trp53. Kaplan-Meier tumor-free survival curves for
K14cre;Cdh1F/F;Trp53F/F versus K14cre;Trp53F/F (upper left panel), K14cre;Cdh1F/+;Trp53F/F (upper right panel), and K14cre;Cdh1F/F;Trp53F/+ (lower left panel)
females. Tumor types for each animal are indicated in colored bullets. Lower right panel shows a tumor-free survival curve of K14cre;Cdh1F/+;Trp53F/F versus
K14cre;Trp53F/F females illustrating that heterozygosity ofCdh1 does not accelerate tumor formation. Mice were killed when tumors reached an average di-
ameter of 10 mm (mammary tumors) or 7 mm (skin tumors). Mammary tumor size was used as the primary criterion.
B:Cdh1and Trp53 inactivation inmammary tumors. Southern blot analysis of tumor DNA todetectCre-mediated inactivation ofCdh1 (ScaI digestion, exon 16
probe) and Trp53 (BglII digestion, exon 11 probe). Shown are representative tumors (T) and control spleens (S) from the same animal. wt/flox, wild-type or con-
ditional allele. D, switched allele.from K14cre;Trp53F/F and K14cre;Cdh1F/+;Trp53F/F females ex-
pressed E-cadherin and showed expansive, rather than invasive
growth (Figure 2, left panels, and Table S1).
Somatic loss of E-cadherin in K14cre;Cdh1F/F;Trp53F/F and
K14cre;Cdh1F/F;Trp53F/+ females resulted in a significant shift
from expansive to invasive carcinoma (p < 0.01; Table 1), which
showed strong phenotypic similarities to human ILC (Figure 2,
middle and right panels). These tumors, which we designate
mouse invasive lobular carcinoma (mILC), developed with high
incidence multifocally in several mammary glands (p < 0.0001;
Table 1). mILC cells were small in size and uniform in appear-
ance. Like the adenocarcinomas and solid carcinomas from
the K14cre;Cdh1F/+;Trp53F/F females, lobular carcinomas fromCANCER CELL NOVEMBER 2006K14cre;Cdh1F/F;Trp53F/F and K14cre;Cdh1F/F;Trp53F/+ females
expressed CK8 and occasionally expressed CK14, but did not
express vimentin (Figure 2, middle panels and Table S1) or
SMA (data not shown), indicating that mILC cells have epithelial
properties. mILCs from K14cre;Cdh1F/F;Trp53F/F and
K14cre;Cdh1F/F;Trp53F/+ females were estrogen receptor (ER)
negative and showed no overexpression of Erbb2 mRNA or
amplification of the Erbb2 gene (data not shown). Also, carcino-
sarcomas were found in K14cre;Cdh1F/F;Trp53F/F and
K14cre;Cdh1F/F;Trp53F/+ females. While displaying mILC com-
ponents, these tumors predominantly exhibited a spindle-
shaped cell morphology, presenting large cells with pleomorphic
nuclei, coarsely clumped chromatin, and sparse cytoplasm.439
A R T I C L EFigure 2. Conditional inactivation of E-cadherin and p53 in mammary epithelium induces mouse invasive lobular carcinoma
Histopathologyofmammary tumors derived fromK14cre;Cdh1F/+;Trp53F/F (left panels) andK14cre;Cdh1F/F;Trp53F/F (middlepanels) femalemiceandahuman
patient diagnosedwith invasive lobular carcinoma (ILC) (right panels). Left panels showan adenocarcinoma derived froma K14cre;Cdh1F/+;Trp53F/F female.
Middle panels show the consequence of homozygous inactivation of E-cadherin in mammary tumors from K14cre;Cdh1F/F;Trp53F/F females. Tumors have un-
dergone a switch from an expansive to an invasive carcinoma resembling human ILC. mILCs are characterized by a trabecular or ‘‘single file’’ arrangement
of cells, are poorly differentiated, and are small in size and uniform in nuclear and cytoplasm. Tumor cells show invasive characteristics, infiltrating abundantly
present fibrous stromal tissues. The bottom H&E stainings show enlargements of the top panels. Scale bars, 100 mm.440 CANCER CELL NOVEMBER 2006
A R T I C L ESpindle-shaped tumor cells showed both expansive and inva-
sive growth patterns, heterogeneously expressed CK8 and
CK14, and mostly expressed vimentin, but lacked expression
of E-cadherin and SMA (Table S1 and data not shown).
Loss of E-cadherin contributes to mammary
tumor initiation
Cre recombinase activity in mammary epithelium of K14cre
transgenic females is relatively low, thus resulting in stochastic
recombination of varying numbers of recombined alleles in indi-
vidual Cre-expressing mammary epithelial cells (Jonkers et al.,
2001). The low activity of K14cre in mammary epithelium is ex-
emplified by the mammary tumors from K14cre;Cdh1F/+;
Trp53F/F females, which show—in addition to uniform recombi-
nation of both conditional Trp53 alleles—stochastic recombina-
tion of the single conditional Cdh1 allele (Figure 1B). Hence, the
fact that the vast majority of primary mammary tumors from
K14cre;Cdh1F/F;Trp53F/F females have lost E-cadherin indi-
cates selection for E-cadherin mutation during primary tumor
formation, suggesting that E-cadherin loss of function con-
tributes to tumor initiation. To verify this, we analyzed macro-
scopically tumor-free mammary glands from K14cre;Cdh1F/F;
Trp53F/F female animals for ductal morphology and E-cadherin
expression. Immunohistochemical staining showed that E-cad-
herin expression was maintained in normal mammary epithelium
of K14cre;Cdh1F/F;Trp53F/F females. However, ducts could be
found partly lined by or filled by atypical cells with luminal char-
acteristics that lacked expression of E-cadherin and showed
increased proliferation (Figure 3), suggesting that these cells
represent an early, noninvasive (in situ) stage of tumor develop-
ment. These findings indicate that loss of E-cadherin not only
promotes mammary tumor progression and metastasis, but
also contributes to tumor initiation in K14cre;Cdh1F;Trp53F
females.
Loss of E-cadherin induces metastatic mILC
To explore whether mILC mimics the metastatic pattern of hu-
man ILC, we performed a detailed histological survey into the
metastatic spread of mILC. From the K14cre;Cdh1F/F;Trp53F/F
and K14cre;Cdh1F/F;Trp53F/+ females that presented carcino-
mas of approximately 1 cm in diameter, 14 out of 21 showed
extensive local invasion (p < 0.01; Table 1), and 10 out of
21 showed metastases to draining and distant lymph nodes
(p < 0.05; Table 1) (Figures 4C and 4D; Table S1). Also, in a
minority of animals dissociated or loosely clustered mILC cells
were detected in organs such as lungs, liver, gastrointestinal
Table 1. Somatic inactivation of E-cadherin leads to invasive and
metastatic mILC in the K14cre;Cdh1F;Trp53F mouse model
K14cre;Cdh1F/+;
Trp53F/F
K14cre;Cdh1F/F;
Trp53F/F c2 p value
Invasive growth* 4/19 (21%) 14/21 (67%) <0.01
Metastasis* 3/19 (16%) 10/21 (48%) <0.05
Adenocarcinoma,
solid carcinoma
13/19 (68%) 5/22 (23%) <0.01
Carcinosarcoma 10/19 (53%) 6/22 (27%) 0.120
mILC 0/19 (0%) 12/22 (54%) <0.0001
*Significance of growth patterns (invasive versus expansive) and metastasis
were calculated for the carcinomas only. Statistical significance (p values)
was determined using a Pearson exact c2 test (two-sided).CANCER CELL NOVEMBER 2006and urogenital tract, and pancreas, or diffusely disseminated
throughout the peritoneal cavity (Figures 4E–4L), indicating
that mILC recapitulates the histopathology and tumor biology
of human ILC. All mILC metastases expressed CK8 and showed
a cellular morphology similar to that of the primary tumor (Fig-
ures 4A–4L and data not shown). Moreover, we frequently
observed mILC cells infiltrating desmoplastic stroma arranged
in single cell rows, forming stellate lesions and occasionally
showing targetoid periductal distributions, which are typical
features of human ILC (Figures 4M–4P). In contrast to the
frequent occurrence of metastasis in K14cre;Cdh1F/F;Trp53F/F
and K14cre;Cdh1F/F;Trp53F/+ females, metastasis was only
sporadically observed in K14cre;Cdh1F/+;Trp53F/F females
(Table 1 and Figure S1). ThreeK14cre;Cdh1F/+;Trp53F/F females
with a mixed carcinosarcoma/carcinoma tumor morphology
showed dissemination of tumor cells to regional lymph nodes
or lungs. Interestingly, one of these tumors had lost expression
of E-cadherin (Table S1).
To investigate the pattern of mILC metastasis in more detail,
we isolated primary mammary tumor cells from K14cre;Trp53F/F
Figure 3. Loss of E-cadherin is an early event in mammary tumor formation
Histopathology of serial sections from a K14cre;Cdh1F/F;Trp53F/F female
mice, showing early in situ lesions lacking E-cadherin (arrow) expression.
Arrowhead indicates a normal mammary duct. MCM7, Cdc47 proliferation
marker. Scale bars, 100 mm.441
A R T I C L EFigure 4. mILC resembles the invasive and metastatic characteristics of human ILC
A and B: Infiltration of the striated muscle of the hind limb by mILC cells, which originate from a primary tumor present in the adjacent fifth mammary gland.
C–F: Distant metastasis of mILC. Carcinoma cells are infiltrating the medullary sinus of the axillary lymph node (arrow) (C and D) and lungs (E and F).
G and H:Gastric involvement in mILC. Sections showing extravasation of mILC cells from the vena gastrica, invading into the muscularis externa of the stom-
ach (arrow). Note the expression of CK8 on the invading ILC cells. V, vein.
I and J: Peritoneal metastasis of mILC. Sections showing mILC metastasis to pancreas.
K and L: Sections showing metastasis of mILC to bladder and liver, respectively.
M–P: mILC displays characteristic features of human ILC. M and N: Stellate lesions in mILC. mILC cells infiltrating desmoplastic stroma arranged in single cell
rows. N is an enlargement of M. O and P: Targetoid periductal distributions in mILC, with periductal infiltration of mILC cells surrounding a normal duct. P is
an enlargement of O.
Sections were stained with H&E (A, C, E, G, I, and K–P) or with antibody against cytokeratin 8 (B, D, F, H, and J). Scale bars, 100 mm.and K14cre;Cdh1F/F;Trp53F/F females, which were cultured and
subsequently transduced with luciferase-encoding lentiviruses.
Mice that were orthotopically transplanted with small numbers
of luciferase-expressing Cdh1D/D;Trp53D/D tumor cells showed
distant metastases, which could be imaged using noninvasive
bioluminescence imaging 5 weeks posttransplantation (Fig-
ure 5A). Metastases were detected in the peritoneal and thoracic
cavity, contralateral mammary glands, and lungs (Figures 5B–5E).
In addition, we detected osteolytic bone metastases in the verte-
brae of the spinal column infiltrating the spinal cord (Figure 5C).
These data show that the full metastatic spectrum of human
ILC is recapitulated by the K14cre;Cdh1F;Trp53F mILC model.
In contrast to Cdh1D/D;Trp53D/D tumor cells, orthotopic
transplantation of luciferase-marked Trp53D/D tumor cells
did not result in local tumor growth and metastasis. In these
animals, the bioluminescence signal decreased to undetect-
able levels over time (Figure 5A), suggesting that orthotopically
transplanted Trp53D/D mammary tumor cells are not able to
survive in the absence of a comprehensive endogenous micro-
environment.442Loss of E-cadherin induces resistance to anoikis
The difference in survival between Trp53D/D and Cdh1D/D;
Trp53D/D tumor cells in situ prompted us to investigate their
in vitro survival characteristics. We therefore cultured cells on
noncoated polystyrene dishes to assess detachment-induced
apoptosis (anoikis). In the absence of cell-matrix interaction,
E-cadherin-expressing Trp53D/D tumor cell lines underwent
anoikis, resulting in more than 70%–80% apoptotic cells after
approximately 4 days of culturing. Interestingly, Cdh1D/D;
Trp53D/D cells could survive and proliferate in an anchorage-
independent fashion, resulting in less than 10%–30% apoptotic
cells after 4 days of culture on a noncoated polystyrene surface
(Figures 6A–6C). Anoikis resistance was observed for cell lines
derived from four independent Cdh1D/D;Trp53D/D primary
tumors, whereas cultured cells from four independent Trp53D/D
tumors showed sensitivity to anoikis (p < 0.005; Figure 6C),
indicating that loss of E-cadherin facilitates survival of mammary
tumor cells in the absence of cell-matrix interactions.
To determine whether loss of E-cadherin directly induces
anchorage-independent cell survival, we tested whetherCANCER CELL NOVEMBER 2006
A R T I C L EFigure 5. In vivo imaging of metastatic mILC
A: Bioluminescence imagingof recipient animals, orthotopically transplantedwith luciferase-transducedmammary tumor cells derived fromaK14cre;Trp53F/F
mouse (top panels) or K14cre;Cdh1F/F;Trp53F/F mouse (bottom panels). The color bar represents bioluminescence intensity counts. Transplantations were
performed in a minimum of ten recipient animals. Results were confirmed using two independent Trp53D/D and two different Cdh1D/D;Trp53D/D cell lines.
B–E: H&E staining of metastases to lungs (B), caudal vertebrae of the spinal column (arrow) (C), contralateral fourth mammary gland (D), and peritoneum,
showing invasion of mILC cells into the diaphragm (E). Scale bars, 100 mm.restoration of E-cadherin expression in Cdh1D/D;Trp53D/D cells
would restore their capacity to undergo anoikis. After transduc-
tion of Cdh1D/D;Trp53D/D cells with ecotropic retroviruses en-
coding mouse E-cadherin, the majority of the E-cadherin-ex-
pressing Cdh1D/D;Trp53D/D cells underwent anoikis, while the
parental Cdh1D/D;Trp53D/D cells survived (Figure 6E). These
data show that E-cadherin reexpression can effectively counter-
act the survival phenotype of Cdh1D/D;Trp53D/D cells, suggest-
ing that loss of E-cadherin plays a causal role in the acquisition
of anoikis resistance.
Induction of angiogenesis in murine ILC
Histological analysis revealed massive central necrosis in E-
cadherin-proficient mammary tumors from K14cre;Cdh1F/+;
Trp53F/F females, whereas necrotic cells were rare or absent
in E-cadherin-deficient tumors from K14cre;Cdh1F/F;Trp53F/F
females (Figure 7A). These findings prompted us to investigate
differences in vascularization between the aforementioned tu-
mors. Staining of tumor sections with the endothelial marker
CD31 showed large numbers of uniformly distributed blood ves-
sels in mILCs from K14cre;Cdh1F/F;Trp53F/F females. In con-
trast, tumors harvested from K14cre;Cdh1F/+;Trp53F/F females
displayed notably less vascularization, present mainly in the
periphery of the tumor (Figure 7B). Quantification of the number
of CD31-positive vessels in viable tumor areas of K14cre;
Cdh1F/+;Trp53F/F and K14cre;Cdh1F/F;Trp53F/F carcinomas
showed a 3-fold increase in vasculature in mILC (p < 0.0001;
Figure 7C).
To verify whether mILC cells are a source of angiogenic fac-
tors, we harvested conditioned medium (CM) from Trp53D/D
and Cdh1D/D;Trp53D/D primary tumor cells cultured under
serum-free conditions and performed an in vitro endothelial
sprouting assay to examine induction of de novo vascularization.
Indeed, CM from Cdh1D/D;Trp53D/D tumor cells inducedCANCER CELL NOVEMBER 2006extensive sprouting of bovine endothelial cells, whereas only
marginal sprouting was observed when endothelial cells were in-
cubated with CM from Trp53D/D tumor cells (Figures 7D and 7E).
These data suggest that E-cadherin loss of function promotes
the expression of proangiogenic factors that mediate tumor vas-
cularization in mILC.
Discussion
Loss of E-cadherin has been extensively implicated in the pro-
gression and dissemination of human cancer (Berx and van
Roy, 2001; Conacci-Sorrell et al., 2002; Cavallaro and Christo-
fori, 2004). Although a plethora of in vitro and clinical data sug-
gest a strong involvement of E-cadherin mutation or silencing in
lobular breast carcinoma, proof of a causal role for E-cadherin
mutation in this malignancy is still lacking. Here, we present
in vivo evidence that E-cadherin loss of function collaborates
with p53 inactivation in the genesis, progression, and metasta-
sis of mammary carcinoma. Furthermore, we impart a mouse
model for human ILC, which represents up to 15% of invasive
breast malignancies.
E-cadherin loss promotes both primary tumor formation
and metastatic disease
Our model shows that E-cadherin acts as a tumor suppressor in
the absence of p53 and that loss of E-cadherin and p53 effec-
tively synergize in tumor formation. While combined inactivation
of E-cadherin and p53 seems a prerequisite for mILC develop-
ment, reduction in E-cadherin gene dosage does not provide
a growth advantage in our model. Although we cannot exclude
the possibility that E-cadherin has been silenced by either ge-
netic or epigenetic mechanisms, selection for loss of the wild-
type Cdh1 allele was not a common feature in tumors from
K14cre;Cdh1F/+;Trp53F/F animals. This finding was unexpected,443
A R T I C L EFigure 6. Loss of E-cadherin induces anoikis resistance
A: Eight primary tumor cell lines derived from independent K14cre;Trp53F/F and K14cre;Cdh1F/F;Trp53F/F mammary tumors were cultured for approximately
4 days on a noncoated polystyrene surface. Scale bars, 80 mm.
B: The percentage of apoptotic tumor cells expressing phosphatidylserine was determined using binding to FITC-conjugated Annexin-V. In the presence of
E-cadherin, tumor cells are not able to survive in the absence of cell-matrix interactions (top panel; Trp53D/D cells). In contrast, mILC cells show anoikis resis-
tance (bottom panel; Cdh1D/D;Trp53D/D cells). Gray lines represent Annexin-V binding of input material.
C:Mammary tumor cell lines derived from four independent K14cre;Trp53F/F tumors (white bars) and four independent K14cre;Cdh1F/F;Trp53F/F tumors (black
bars) were assayed for anoikis resistance as in B. Error bars represent the standard deviation of triplicate measurements.
D: Reintroduction of functional E-cadherin in Cdh1D/D;Trp53D/D cells. Cdh1D/D;Trp53D/D cells were transduced and stained for E-cadherin (top panels) and
b-catenin (middle panels). Blue represents nuclear DNA staining using ToPro-3. Scale bars, 15 mm.
E: Restoration of epithelial characteristics and anoikis sensitivity upon expression of exogenous E-cadherin. Cdh1D/D;Trp53D/D cells (left panels) were trans-
duced with E-cadherin (center and right panels). Photographs show the induction of epithelial cell morphology (center and right panels; scale bars,
20 mm). Transducedcells were then cultured for 2 days ona noncoatedpolystyrene surfaceandassayed for apoptosis (dot plots). Early apoptotic populations
(encircled; Annexin-V-positive/Topro-3-negative) were gated andanalyzed for E-cadherin expression (histograms). Red lines represent E-cadherin expression
signal of early apoptotic Cdh1D/D;Trp53D/D cells.considering that E-cadherin loss of function in sporadic breast
cancer frequently occurs by loss of heterozygosity (LOH) (Vos
et al., 1997; Berx et al., 1998) or epigenetic silencing (Cano
et al., 2000; Comijn et al., 2001; Hajra et al., 2002; Yang et al.,
2004). This difference may be explained by the fact that the ef-
ficiency of Cre-mediated deletion in K14cre-expressing mam-
mary epithelial cells is approximately 60% per conditional allele
(Jonkers et al., 2001), whereas LOH occurs with a much lower
efficiency of approximately 1024 per cell generation per allele
(Adams and Bradley, 2002). Consequently, mammary tumori-
genesis in K14cre;Cdh1F/+;Trp53F/F mice may be dominated
by p53 inactivation in combination with oncogenic mutations444that may occur more efficiently and/or collaborate more effec-
tively with p53 abrogation than E-cadherin LOH. Of note, syn-
ergy between p53 abrogation and E-cadherin inactivation is
clearly demonstrated by the accelerated tumor development
in K14cre;Cdh1F/F;Trp53F/F mice compared to K14cre;Cdh1F/F
animals.
K14cre-mediated conditional inactivation of E-cadherin alone
in mammary epithelium does not predispose to tumors. This is
probably due to the fact that E-cadherin loss in mouse mam-
mary epithelium is not tolerated as a result of the rapid induction
of apoptosis (Boussadia et al., 2002). In concordance with
this, we did not detect ductal structures lacking E-cadherinCANCER CELL NOVEMBER 2006
A R T I C L EFigure 7. Induction of angiogenesis in murine ILC
A and B: Increased vascularization in vivo in mILC. A: H&E staining showing abundant necrosis (arrow) in K14cre;Cdh1F/+;Trp53F/F mammary tumors (left
panels), whereas in K14cre;Cdh1F/+;Trp53F/F mILC (right panels) necrosis is absent. Bottom panels are a magnification of the upper panels. Scale bars,
1 mm (top panels) and 100 mm (bottom panels). B: Histopathology of K14cre;Cdh1F/+;Trp53F/F (left panel) and K14cre;Cdh1F/F;Trp53F/F (right panel) mammary
tumors showing CD31 expression. Note the abundantly present CD31-positive vessels in mILC. Arrow indicates a necrotic area. Scale bars, 50 mm.
C: Quantification of the vascular density. The number of CD31-positive vessels were counted in ten low-power fields in tumors derived from three
K14cre;Cdh1F/+;Trp53F/F females (white bars) and three K14cre;Cdh1F/F;Trp53F/F females (black bars). p values were calculated using ANOVA.
D and E: mILC induces in vitro angiogenesis. Bovine microvascular endothelial cells (BCEs) were cultured in a collagen matrix, after which serum-free CM
from primary mammary tumors was added. Sprouting was induced more abundantly in the presence of conditioned medium (CM) from Cdh1D/D;
Trp53D/D cells than in the presence of CM from Trp53D/D cells. Sprouting shown in Dwas quantified in E. Error bars represent the standard deviation of triplicate
measurements.CANCER CELL NOVEMBER 2006 445
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E-cadherin-negative epithelial in situ lesions in mammary glands
from tumor-free K14cre;Cdh1F/F;Trp53F/F females. Loss of
E-cadherin in this setting appears to be an early, tumor-initiating
event, which is most likely tolerated because the apoptotic
signals that are induced upon E-cadherin inactivation cannot
be executed in the absence of functional p53.
Several biological programs have to be deregulated in order
to transform normal cells into malignant, metastatic tumor cells
(Hanahan and Weinberg, 2000). Loss of p53 results in loss of ap-
optotic responses and cell cycle control. This is, however, not
sufficient to develop metastatic disease, as K14cre;Trp53F/F
and K14cre;Cdh1F/+;Trp53F/F females develop mammary carci-
nomas that only sporadically metastasize within the life span of
the animals. Concomitant somatic loss of E-cadherin may pro-
vide key signals that promote tumor cell metastasis. First,
mILC cells have acquired the potential to invade the surrounding
stroma, which requires an increase in mobility and expression of
the appropriate adhesion receptors. Second, the extremely
dense and homogeneously distributed vascularization, as well
as the capacity of mILC cells to function as a paracrine source
of proangiogenic factors, indicate that somatic loss of E-cad-
herin may render mILC cells capable of inducing or enhancing
angiogenesis. Finally, mILC cells have acquired anoikis resis-
tance, which can facilitate tumor metastasis by permitting these
cells to survive within the bloodstream and the lymphatic system
and at distant organ sites. These findings imply that loss of E-
cadherin invokes the capability to counteract the strong (p53-in-
dependent) proapoptotic signals that are induced upon loss of
cell-matrix interactions. In summary, we conclude that, in our
mILC model, loss of E-cadherin not only confers selective ad-
vantage during early stages of tumor development, but also pro-
motes tumor progression and metastatic disease. Together,
these findings support the notion that the signature of the pri-
mary tumor is a major determinant for clinical outcome (Van ’t
Veer et al., 2002). E-cadherin may thus represent a prime exam-
ple of a tumor suppressor that fits the same-gene hypothesis,
which states that certain mutations that provide a selective ad-
vantage during tumor initiation can also foster an invasive and
metastatic phenotype (Hanahan and Weinberg, 2000; Bernards
and Weinberg, 2002).
E-cadherin loss induces a phenotypic change
from expansive adenocarcinoma to invasive
lobular carcinoma
During mammary gland development, pluripotent cells can form
both myoepithelial and luminal epithelial cell lineages. These
cells, which express CK14, are thought to represent the mam-
mary stem cells (Smalley and Ashworth, 2003; Althuis et al.,
2005; Shackleton et al., 2006; Stingl et al., 2006). All mammary
carcinomas from the K14cre;Cdh1F;Trp53F model showed sim-
ilar epithelial phenotypes, characterized by expression of the lu-
minal marker CK8, occasional expression of the myoepithelial
marker CK14, and absence of SMA and vimentin. However,
the majority of K14cre;Cdh1F/F;Trp53F/+ and K14cre;Cdh1F/F;
Trp53F/F females developed invasive lobular instead of expan-
sive carcinomas, indicating that the formation of mILC is a direct
consequence of E-cadherin loss of function. E-cadherin is
known to be important for both cell-cell adhesion and cell polar-
ity (Drubin and Nelson, 1996), and it is therefore conceivable that
loss of these functions may impair the duct-forming capacity of446mammary epithelial cells. While the cell of origin remains elusive,
our data are compatible with the notion that ductal and lobular
carcinomas may originate from a common (CK14-positive) pro-
genitor cell (Wellings et al., 1975; Wellings, 1980) and raise the
possibility that the lobular carcinoma phenotype may directly
result from loss of E-cadherin-mediated cell adhesion.
E-cadherin loss does not induce classical
epithelial-to-mesenchymal transition
Numerous reports have shown that several transcription repres-
sors of E-cadherin, such as SIP1, Snail, Slug, and Twist (Savag-
ner et al., 1997; Batlle et al., 2000; Cano et al., 2000; Comijn
et al., 2001; Hajra et al., 2002; Yang et al., 2004) can induce
epithelial-to-mesenchymal transition (EMT) and subsequent
metastasis. It has therefore been suggested that E-cadherin
may be an important caretaker of the epithelial phenotype
(Thiery, 2002). Our data show that E-cadherin loss alone is not
sufficient for EMT, since all mILCs from our K14cre;Cdh1F/F;
Trp53F/F model express the epithelial marker CK8 and lack ex-
pression of mesenchymal markers such as vimentin. Moreover,
no significant difference in the incidence of carcinosarcomas
was observed between K14cre;Cdh1F/+;Trp53F/F and K14cre;
Cdh1F/F;Trp53F/F females (Table 1). While we cannot exclude
the possibility that mILC cells transiently acquire mesenchymal
properties during tumor invasion and dissemination, mILC might
not require a complete EMT in order to metastasize. Conversely,
the loss of E-cadherin-mediated cell adhesion and the spindle-
shape morphology of mILC cells could be regarded as a partial
EMT. It will therefore be important to determine whether tumor
cell metastasis induced by expression of EMT regulators such
as SIP1, Snail, Slug, and Twist is solely mediated through
repression of E-cadherin, or whether other transcriptional tar-
gets contribute to this process.
ILC in mice and men
Mouse ILC recapitulates several key features of human ILC, in-
cluding cellular morphology, absence of Her2/Neu/Erbb2 ex-
pression, invasive growth patterns, and sites of metastasis.
Nevertheless, there are also differences between mILC and
human ILC. One important discrepancy is that, in contrast to
human ILC, mILCs do not express estrogen receptors. This dif-
ference is in line with the fact that, whereas most human breast
cancers are ER positive, most established mouse models
develop ER-negative mammary tumors (Nandi et al., 1995).
Another potential difference between mILC and human ILC is
the involvement of p53 mutations, which are thought to occur
in a minority (4%–25%) of human ILC cases (Marchetti et al.,
1993; Rosen et al., 1995; Soslow et al., 2000; Coradini et al.,
2002; Arpino et al., 2004). Most analyses, however, have been
performed using immunohistochemical detection of mutant
p53 protein, leaving the possibility of functional p53 loss through
alternative mechanisms. Supporting this are recent studies
showing that 30%–40% of human lobular carcinomas have
lost the TP53 locus on chromosome 17p13 (Mohsin et al.,
2005; Stange et al., 2006).
In summary, we have shown that somatic loss of E-cadherin
and p53 in mice induces mammary tumors with histological
characteristics similar to human ILC, a malignancy for which
no mouse model was available until now. Concomitant loss of
E-cadherin and p53 orchestrates a complex tactic that impacts
on multiple aspects of oncogenesis, including tumor initiation,CANCER CELL NOVEMBER 2006
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mILC model may prove a valuable tool for the identification of
the molecular consequences of E-cadherin inactivation during
mammary tumorigenesis and may facilitate designing and test-
ing of treatment modalities for human ILC.
Experimental procedures
Construction of targeting vectors
To target the Cdh1 locus, we isolated two clones from a mouse 129/Sv PAC
library (RPCI-21, BACPAC Resources) using probes directed against exons 7
and 8 of Cdh1. From the PAC clones, 12 kb and 7.0 kb BamHI fragments
were isolated using probes against Cdh1 exons 4 and 14, respectively. The
50 targeting construct was generated from the 12 kb BamHI fragment by in-
serting a loxP-PGKneo-loxP cassette into a unique AvrII site present in Cdh1
intron 3. For the 30 targeting construct, we used the 7 kb BamHI fragment to
insert a loxP-PGKhygro-loxP cassette into a unique EcoRV site present in
Cdh1 intron 15.
Generation of Cdh1F/+ conditional mice
A sequential gene targeting approach was undertaken to introduce single
loxP sites in introns 3 and 15 of murine Cdh1 (Figures S1A–S1C). The 50
and 30 targeting constructs were released from the pGEM5 vector by NotI di-
gestion. The 50 targeting construct was electroporated into 129/Ola-derived
E14-IB10 ES cells (Robanus-Maandag et al., 1998), and correctly targeted
neomycin-resistant ES cells were identified by Southern blot analysis. One
of these clones was subsequently electroporated with the 30 targeting con-
struct and subjected to hygromycin selection. Following identification of pos-
itive clones by Southern blot analysis, removal of the neomycin and hygrom-
ycin selection markers was achieved by transient Cre expression as
described (Jonkers et al., 2001). Clones were analyzed by PCR using primers
P1 (50-ACATGTTTGTATCGATCTCAG-30) and P2 (50-CCATACACTGATAAT
GTCAGA-30) to detect deletion of the neomycin cassette and primers P3
(50-TCAATCTCAGAGCCCCACCTA-30) and P4 (50-CCTGCCATGATTGTCA
TGGAC-30) to detect deletion of the hygromycin cassette, thus leaving be-
hind single loxP sites in introns 3 and 15, respectively. Next, we confirmed
dual targeting in cis by Southern blot analysis of SacI-digested DNA from
positive ES cell clones with a Chd1 exon 3 probe. The resulting Cdh1F/+ ES
cells were injected into C56Bl/6 blastocysts, and chimeras were crossed
with FVB/N mice to produce heterozygous offspring. The resulting Cdh1F/+
heterozygous and Cdh1F/F homozygous mice were viable and fertile and
showed a normal life span, indicating that the Cdh1F allele is fully functional.
To test whether tissue-specific deletion of Cdh1 exons 4 to 15 leads to func-
tional inactivation of E-cadherin, we crossed Cdh1F/F homozygotes with
K14cre transgenic mice, which express the Cre recombinase in several epi-
thelial tissues, including skin and mammary epithelium (Jonkers et al., 2001).
The resulting K14cre;Cdh1F/F animals showed stochastic loss of E-cadherin
protein expression in skin epithelium, demonstrating that deletion of exons 4
to 15 of E-cadherin results in a functional null allele (Figure S1D). In contrast to
the phenotypically normal K14cre;Cdh1F/+ animals, K14cre;Cdh1F/F mice
showed developmental defects in skin epithelium, resulting in disturbed
hair follicle development, epidermal hyperplasia with frequent inflammation,
progressive hair loss, and abnormal sebaceous gland development (data not
shown). All animal experiments were approved by the Animal Ethical Com-
mittee and conducted in compliance with the Netherlands Cancer Institute
and Dutch Animal Welfare guidelines.
DNA analysis
Genomic DNA was isolated from tissue by proteinase K lysis and organic ex-
traction with phenol-chloroform. We performed Southern blot analysis using
10 mg of gDNA, digested with BglII or ScaI, to determine the status of the
Trp53 and Cdh1, respectively. Blotting and hybridization was performed as
described (Jonkers et al., 2001). The Trp53 probe has been described
(Jonkers et al., 2001). The Cdh1 probe was generated by PCR amplification
of a 250 bp fragment of exon 16 using primers 50-TTGAAGGATGCACC
GGCCGGC-30 and 50-GGCGTGGTGGTGCCGGTGATG-30. Probes were
radiolabeled by PCR.CANCER CELL NOVEMBER 2006Genotyping of mutant mice
Detection of the K14cre, Trp53F, and Trp53D alleles was done as described
previously (Jonkers et al., 2001). We detected the Cdh1F allele by PCR am-
plification of the loxP site in intron 15, using primer pair P1 and P2, yielding
270 bp and 330 bp for the wild-type and floxed alleles, respectively. The de-
leted allele, Cdh1D, was detected by PCR using primers P1 and P4, yielding
a product of 320 bp. PCR conditions were as described (Jonkers et al., 2001).
Antibodies
The following antibodies were used: (FITC-conjugated) mouse anti-E-
cadherin (1:300; BD Biosciences), mouse anti-E-cadherin (1:1000; Zymed),
rat anti-E-cadherin (DECMA-1; 1:2000) (Sigma), mouse anti-b-catenin
(1:150; BD Biosciences), rat anti-cytokeratin (CK) 8 (Troma-1; 1:125; DSHB
products), mouse anti-CK8 (CAM5.2; 1:400; BD Biosciences), rabbit
anti-CK14 (1:10,000; BabCo), mouse anti-CK14 (1:200; Neomarkers), guinea
pig anti-vimentin (1:400; RDI), mouse anti-vimentin (3B4; 1:400), mouse
anti-SMA (1:10; Zymed), rabbit anti-SMA (1:350; Lab Vision), and goat anti-
CD31 (1:200; Santa Cruz). Secondary antibodies were as follows: biotin-con-
jugated anti-mouse, anti-rat and anti-rabbit antibodies (DAKO), biotin-conju-
gated anti-guinea pig (Jackson ImmunoResearch), Alexa 568-conjugated
anti-mouse (Molecular Probes), and RPE-conjugated anti-rat (Southern
Biotechnology Associates).
Histological analysis
Tissues were isolated and fixed in 4% formaldehyde for 48 hr. Tissues were
dehydrated, cut into 4 mm sections, and stained with hematoxylin and eosin.
For single staining, fixed sections were rehydrated and incubated with pri-
mary antibodies. Endogenous peroxidases were blocked with 3% H2O2
and stained with biotin-conjugated secondary antibodies, followed by incu-
bation with HRP-conjugated streptavidin-biotin complex (DAKO). Substrate
was developed with either AEC or DAB (DAKO). For immunofluorescence,
cells were grown on coverslips and fixed in ice-cold methanol. Cells were
permeabilized using 0.5% Triton/PBS and subsequently incubated with pri-
mary antibodies. Then, cells were incubated with fluorochrome-conjugated
secondary antibodies. DNA was stained with ToPro-3 (Molecular Probes),
and cells were analyzed by confocal laser microscopy.
Cell culture
For the isolation of primary tumor cells, 50–100 mm3 tumor sample was finely
chopped using a McIlwain tissue chopper (The Mickle Laboratory Engineer-
ing Co.) and digested for 1 hr at 37C in serum-free DMEM-F12 medium (In-
vitrogen Life Technologies) containing 0.1 mg/ml porcine pancreatic trypsin
(Difco) and 0.2 mg/ml collagenase A (Roche). Cells were washed and fibro-
blasts were allowed to adhere for 1 hr at 37C. Nonadherent epithelial cells
were removed and cultured in DMEM-F12 medium containing 10% fetal bo-
vine serum (FBS; ICN), 100 IU/ml penicillin, 100 mg/ml streptomycin, 5 ng/ml
insulin, 5 ng/ml epidermal growth factor (EGF) (all Invitrogen Life Technolo-
gies), and 5 ng/ml cholera toxin (Sigma). 293T cells were cultured in Iscove’s
medium (Invitrogen Life Technologies) containing 10% FBS, 100 IU/ml pen-
icillin, and 100 mg/ml streptomycin.
Retroviral production and transduction of cells
The mouse E-cadherin cDNA (a kind gift from Dr. G. Christofori, University of
Basel, Switzerland) was subcloned into pBABE-puro and pMSCV-blast ret-
roviral vectors. For production of ecotropic retroviruses, 106 Phoenix pack-
aging cells were seeded onto 10 cm petri dishes and transiently transfected
after 24 hr with either pBABE-Cdh1 or pMSCV-Cdh1 using Fugene-6 trans-
fection reagent (Roche). Supernatant containing viral particles was harvested
after 72 hr and passed through a 45 mm filter. Retroviral infection of tumor
cells was performed three times for 4 hr in the presence of 4 mg/ml polybrene
(Sigma). Lentiviral particles were produced by seeding 106 293T cells onto
a 10 cm petri dish and transient transfection after 24 hr with third-generation
packaging constructs (Dull et al., 1998) and a luciferase-encoding transfer
vector (LV-luc). The LV-luc vector was constructed by replacing the GFP
coding region from pCSCG (Miyoshi et al., 1998) with the luciferase coding
sequence from pNF-kB-Luc (Clontech). Supernatant containing lentiviral
particles was harvested after 48 and 72 hr, passed through a 45 mm filter,
and concentrated by centrifugation at 20,000 rpm for 2.5 hr. Virus particles
were dissolved in serum-free DMEM-F12 (Invitrogen), snap frozen in liquid447
A R T I C L Enitrogen, and stored at 280C. Tumor cells were infected with LV-luc for 16
hr in the presence of 4 mg/ml polybrene.
Orthotopic transplantations and bioluminescence imaging
Three-week-old Rag22/2;IL2Rgc2/2 BALB/c females (Gimeno et al., 2004)
were anesthetized by intraperitoneal (i.p.) injection of a mixture containing
25 ml hypnorm (Janssen Pharmaceutica), 25 ml dormicum (Roche), and
50 ml water. The fourth mammary gland was exposed, and endogenous
mammary epithelial tissue was removed. Next, approximately 10,000 lucifer-
ase-transduced tumor cells were injected in the cleared fat pad using a Ham-
ilton syringe, after which the animals were sutured. After a recovery period of
2 weeks, mice were anesthetized with isofluorane (Janssen Pharmaceutica),
injected i.p. with 225 mg/g body weight n-luciferin (potassium salt; Xenogen
Corp.), and imaged on a IVIS-100 bioluminescence imager (Xenogen Corp.).
Anoikis assay
Cells were plated at a density of 75,000 cells per well in a 6-well ultra-low
cluster polystyrene culture dish (Corning). After the indicated time interval,
cells were harvested and incubated at 37C with 0.25% trypsin (Invitrogen)
for 1 min to prevent cell aggregation. FITC-conjugated Annexin-V (IQ Prod-
ucts) and ToPro-3 (Molecular Probes), were added and Annexin-V-positive
apoptotic cells were analyzed by FACS as described (Derksen et al., 2003).
Statistical significance was calculated using the Student’s t test.
Sprouting assay
Bovine microvascular endothelial cells (BCEs), kindly provided by Dr. M.
Furie (State University of New York, Stony Brook, NY), were cultured on gel-
atin-coated flasks in DMEM supplemented with 10% FBS (Perbio Science),
50 IU/ml penicillin, 50 ng/ml streptomycin, and 30 mg/ml endothelial cell
growth supplement (ECGS; BD Biosciences). BCEs were mixed with gela-
tin-coated cytodex-3 beads (Sigma) at a concentration of 100 cells per
bead and cultured for 72 hr in BCE medium supplemented with 25%
serum-free conditioned medium from Trp53D/D or Cdh1D/D;Trp53D/D mILC
cells. The beads were subsequently resuspended at a concentration of
25 beads per 100 ml in a collagen gel mixture consisting of 2.4 mg/ml vitro-
gen-100 (Collagen, Fremont, CA), 13 a-MEM (Life Technologies), and
1.2 mg/ml sodium bicarbonate (Merck). Solidified gel was overlaid with
BCE medium supplemented with serum-free 25% conditioned medium
from the indicated cell lines, 20 ng/ml bFGF (Reliatech), or DMEM as control.
Photographs were taken after 48 hr. Five concentric rings were projected
over the photographs, and the number of intersections of rings and sprouting
endothelial cells was determined and used as a measure of in vitro tube
formation. Statistical analyses were done using the Student’s t test.
Supplemental data
The Supplemental Data include three supplemental figures and one supple-
mental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/10/5/437/DC1/.
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